ReviewViruses2019
The Clinical Perspective on Hepatitis E.
Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06457438 (Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors), which is not on this map. Cited by 77 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
Who cites it
77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Hepatitis E Infection in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- The burden of HEV-related acute liver failure in Bangladesh, China and India: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- The Prevalence of Hepatitis E Virus Infection in the Adult Turkish Population: A Systematic Review of the Literature and Prevalence Study in Blood Donors in Mersin Province.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Pooled it
- Hospital Admissions for Hepatitis A and E in Spain: Nationwide Trends and In-Hospital Outcomes.Journal of medical virology · 2026Article
- Hepatitis E virus infection: considerations for immunologists and rheumatologists.Rheumatology international · 2026Review
- Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- High hepatitis E virus prevalence in pig slurry samples from the north-western region of Germany.One health (Amsterdam, Netherlands) · 2026Article
- The Value of Hepatitis E Screening Sensitivity: Lookback Investigation in German Blood Donors.Viruses · 2026Article
- Sexual transmission of hepatitis E virus via vaginal and rectal routes in a rabbit model.The Journal of general virology · 2026Article
- Extended Duration of Anti-HEV IgM Seropositivity in Asymptomatic Blood Donors: Implications for Transfusion Safety.Viruses · 2026Article
- Performance of Elecsys Anti-HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Hepatitis E virus (HEV) as an emerging challenge in Poland: a narrative review of epidemiological and clinical data.Archives of medical science : AMS · 2026Article
- Hepatitis E virus in immunocompromised children in Argentina: first report from a high-risk group.Virology journal · 2025Article
- Article
- Design and Analysis of Novel HEV Vaccine Variants and Evaluation of Two Selected Candidates in a Porcine Infection Model.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- The hepatitis E virus capsid protein ORF2 counteracts cell-intrinsic antiviral responses to enable persistent replication in cell culture.PLoS pathogens · 2025Article
- Integrin beta 1 facilitates non-enveloped hepatitis E virus cell entry through the recycling endosome.Nature communications · 2025Article
- Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations.Vaccines · 2025Review
- Plasmid-Based Reverse Genetics System Enabling One-Step Generation of Genotype 3 Hepatitis E Virus.Viruses · 2025Article
- Hepatitis E Virus in the Role of an Emerging Food-Borne Pathogen.Microorganisms · 2025Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every year, there are an estimated 20 million hepatitis E virus (HEV) infections worldwide, leading to an estimated 3.3 million symptomatic cases of hepatitis E. HEV is largely circulating in the west and is associated with several hepatic and extrahepatic diseases. HEV Genotype 1 and 2 infections are waterborne and causative for epidemics in the tropics, while genotype 3 and 4 infections are zoonotic diseases and are mainly transmitted by ingestion of undercooked pork in industrialized nations. The clinical course of these infections differs: genotype 1 and 2 infection can cause acute illness and can lead to acute liver failure (ALF) or acute on chronic liver failure (ACLF) with a high mortality rate of 20% in pregnant women. In contrast, the majority of HEV GT-3 and -4 infections have a clinically asymptomatic course and only rarely lead to acute on chronic liver failure in elderly or patients with underlying liver disease. Immunosuppressed individuals infected with genotype 3 or 4 may develop chronic hepatitis E, which then can lead to life-threatening cirrhosis. Furthermore, several extra-hepatic manifestations affecting various organs have been associated with ongoing or previous HEV infections but the causal link for many of them still needs to be proven. There is no approved specific therapy for the treatment of acute or chronic HEV GT-3 or -4 infections but off-label use of ribavirin has been demonstrated to be safe and effective in the majority of patients. However, in approximately 15% of chronically HEV infected patients, cure is not possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.